Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novavax Licenses Wyeth's VLP Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novavax Licenses Wyeth’s VLP Technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novavax, Inc. signed a non-exclusive, worldwide license agreement with Wyeth for the rights to a patent application covering virus-like particle (VLP) technology for vaccines. The agreement includes an upfront payment, annual license fees, milestone payments and royalties on any product sales. Payments to Wyeth could total $5 million through 2008.

Novavax is developing pandemic and seasonal flu vaccines based on the VLP technology. VLPs mimic the three-dimensional structure of a virus but do not contain genetic material, thus they cannot replicate and cause infection or disease. VLPs have been shown to activate multiple responses in the immune system.

“We are delighted to have completed this license agreement with Wyeth and see this license as another important step in building a strong intellectual property position for our influenza vaccine programs,” stated Rahul Singhvi, president and chief executive officer of Novavax.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters